A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs SAR 440340 (Primary) ; Corticosteroids
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 30 Jan 2019 Planned End Date changed from 23 Apr 2020 to 1 Apr 2020.
- 30 Jan 2019 Planned primary completion date changed from 6 Dec 2019 to 1 Dec 2019.
- 21 Jan 2019 Planned primary completion date changed from 23 Apr 2020 to 6 Dec 2019.